Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS12004 in Advanced Solid Tumors
NCT05829616Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS12004 in solid tumor and Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Qilu Pharmaceutical. Primary endpoints: Adverse Events up to 2 years, Dose Limiting Toxicity and 2 more. Status: unknown.
02
Drugs
QLS12004
03
Conditions
solid tumorBreast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05829616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829616.